• HempFusion Wellness (CBD.U) has increased the size of its non-brokered private placement to over US$2,500,000 due to demand from retail investors
  • The closing of the offering has been extended to September 30, 2021
  • HempFusion announces that David Doherty has resigned as a director of the company
  • HempFusion Wellness, a health & wellness CBD company, distributes its family of brands to 15,000 retail locations across the United States and internationally
  • HempFusion Wellness (CBD.U) is up 6.25 per cent, trading at C$0.245 per share at 12:45 pm ET

HempFusion Wellness (CBD.U) has increased the size of its previously announced non-brokered private placement to over US$2,500,000.

“We received quite a few requests from our large network of retail investors, brokers, and funds, to allow further access into this small strategic private placement,” commented Dr. Jason Mitchell, HempFusion’s Co-founder and Chief Executive Officer.

“While we continue to maintain a strong balance sheet, the incoming funds represent strong investors with expected long term time horizons, and we’re excited to welcome them into our company at such a pivotal time.”

The closing of the offering has been extended to September 30, 2021, and remains subject to the approval of the Toronto Stock Exchange.

In other news, HempFusion announces that David Doherty has resigned as a director of the company effective September 17, 2021. The board of directors of the company expresses their appreciation to Mr. Doherty for his contributions.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion Wellness Inc. distributes its family of brands, including HempFusion, Probulin Probiotics, Sagely Naturals, and Apothecanna, to approximately 15,000 retail locations across the U.S. and select international locations. 

HempFusion Wellness (CBD.U) is up 6.25 per cent, trading at C$0.245 per share at 12:45 pm ET.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.